A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPAND
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2018 According to a Novartis media release, results from this study are being presented at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.
    • 20 Apr 2018 Post hoc analysis results presented in the Novartis media release.
    • 22 Mar 2018 Results presented in a Novartis Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top